MARGINAL ZONE LYMPHOMA

This study looked at a new way to do bone marrow transplants for people with blood cancers like leukemia and lymphoma who don't have a perfectly matched donor. Instead of using the standard drug cyclophosphamide after transplant, doctors tested replacing it with another drug call…

This study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs …

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This early-stage study tested a new drug called PRT2527 in 86 people with blood cancers like lymphoma and leukemia that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug works, both alone and combined with other…

This study tested a combination of drugs called VR-CAP as a first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. 26 patients received the treatment to see if it could control the disease for at least 2 years without progression. The goal was to mea…

This study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had bad side effects from similar drugs like ibrutinib or acalabrutinib. The main goal was to see if zanubrutinib causes…

This early-stage trial tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers or advanced solid tumors. The goal was to find safe doses and check for side effects. The study was completed but did not determine the be…

This study tested a one-time treatment using a person's own immune cells, modified to attack cancer, in 159 adults with follicular or marginal zone lymphoma that had returned after at least two prior therapies. The main goal was to see how many patients had their tumors shrink or…

This study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…

This study tested a new radioactive tracer called 18F-BL40, used in PET/CT scans, to see if it can better detect certain blood cancers like lymphoma and multiple myeloma. Ten adults with these cancers received two scans—one with the new tracer and one with a standard tracer—to co…